NewAmsterdam Pharma Stock (NASDAQ:NAMS)
Previous Close
$35.61
52W Range
$14.06 - $42.00
50D Avg
$36.70
200D Avg
$25.22
Market Cap
$4.10B
Avg Vol (3M)
$1.15M
Beta
0.05
Div Yield
-
NAMS Company Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| VKTX | Viking Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| CGON | CG Oncology, Inc. Common stock |
| LGND | Ligand Pharmaceuticals Incorporated |
| AKRO | Akero Therapeutics, Inc. |
| IMVT | Immunovant, Inc. |